Wall Street Zen Downgrades Integra LifeSciences (NASDAQ:IART) to Hold

Integra LifeSciences (NASDAQ:IART) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

IART has been the topic of several other research reports. Wells Fargo & Company dropped their price target on Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Friday, February 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Reduce” and an average target price of $14.80.

Integra LifeSciences Trading Down 1.6%

Shares of Integra LifeSciences stock opened at $9.73 on Friday. The firm’s 50 day simple moving average is $11.72 and its two-hundred day simple moving average is $13.04. The firm has a market capitalization of $758.33 million, a price-to-earnings ratio of -1.45 and a beta of 1.02. Integra LifeSciences has a 12-month low of $9.36 and a 12-month high of $24.36. The company has a current ratio of 2.54, a quick ratio of 1.46 and a debt-to-equity ratio of 1.66.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.79 by $0.04. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The business had revenue of $434.93 million during the quarter, compared to the consensus estimate of $429.62 million. During the same period in the previous year, the firm posted $0.97 earnings per share. The business’s revenue for the quarter was down 1.7% compared to the same quarter last year. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Analysts predict that Integra LifeSciences will post 2.45 EPS for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Large investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Integra LifeSciences by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after buying an additional 1,975 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Integra LifeSciences during the 1st quarter worth approximately $277,000. Goldman Sachs Group Inc. lifted its position in shares of Integra LifeSciences by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock valued at $36,515,000 after buying an additional 35,790 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Integra LifeSciences by 23.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock valued at $5,373,000 after acquiring an additional 45,693 shares during the period. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in Integra LifeSciences in the 2nd quarter valued at $632,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.